deltatrials
Completed PHASE3 NCT02574455

Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)

An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments

Sponsor: Gilead Sciences

Conditions Breast Cancer
Interventions Capecitabine Eribulin Gemcitabine Sacituzumab govitecan Vinorelbine
Updated 31 times since 2017 Last updated: May 26, 2022 Started: Nov 7, 2017 Primary completion: Mar 30, 2020 Completion: Dec 8, 2020

Listed as NCT02574455, this PHASE3 trial focuses on Breast Cancer and remains completed. Sponsored by Gilead Sciences, it has been updated 31 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

31 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jul 2022 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2022 — Jul 2022 [monthly]

    Completed PHASE3

▶ Show 26 earlier versions

  1. Oct 2021 — Jan 2022 [monthly]

    Completed PHASE3

  2. May 2021 — Oct 2021 [monthly]

    Completed PHASE3

  3. Jan 2021 — May 2021 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  4. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  5. Sep 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE3

  6. Jul 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  7. Jun 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE3

  8. Mar 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE3

  9. Jan 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  10. Oct 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  11. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE3

  12. May 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

  13. Mar 2019 — May 2019 [monthly]

    Recruiting PHASE3

  14. Jan 2019 — Mar 2019 [monthly]

    Recruiting PHASE3

  15. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  16. Sep 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  17. Jul 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  18. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  19. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  20. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE3

  21. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE3

  22. Dec 2017 — Mar 2018 [monthly]

    Recruiting PHASE3

  23. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  24. Apr 2017 — Nov 2017 [monthly]

    Not Yet Recruiting PHASE3

  25. Feb 2017 — Apr 2017 [monthly]

    Not Yet Recruiting PHASE3

  26. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gilead Sciences
Data source: Gilead Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain, Albany, United States, Alexandria, United States, Alhambra, United States, Alpharetta, United States, Altamonte Springs, United States, Angers, France, Arlington, United States, Arlington Heights, United States, Athens, United States and 175 more location s